WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study
Alaa Embaby, Joachim Kutzera, Jill J.J. Geenen, Dick Pluim, Ingrid Hofland, Joyce Sanders, Marta López‐Yurda, Jos H. Beijnen, Alwin D. R. Huitema, Petronella O. Witteveen, Neeltje Steeghs, Gijs van Haaften, Marcel A.T.M. van Vugt, Jeroen de Ridder, Frans L. Opdam
Topics & Concepts
CarboplatinMedicineNauseaInternal medicineOncologyClinical endpointVomitingOvarian cancerPhases of clinical researchAdverse effectToxicityGastroenterologyBone marrow suppressionSurgeryCancerChemotherapyRandomized controlled trialCisplatinOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyPI3K/AKT/mTOR signaling in cancer